Immediately after the FDA said it found elevated levels of the carcinogenic ingredient N-nitrosodimethylamine (NDMA) in certain extended release (ER) metformin products, the first 2 major recalls are underway.
Formulary Watch
Latest News
All News
Advertisement
IV artesunate is the only drug available in the U.S. to treat the disease.
FDA authorizes first stand-alone, at-home test, plus other top COVID-19 news stories.
Antigen tests, a new category, have a major advantage and disadvantage over COVID-19 tests already approved.
Numerous PPEs and testing kits also feature unproven coronavirus claims.
Formulation could cause fewer administration-related reactions than IV Darzalex.
Popular heartburn medication now in shortage due to COVID-19 test.
Agency says the anti-malaria drug can cause heart rhythm problems.
Suppliers claim CBD can help alleviate opioid addiction, cure diseases.
Advertisement
The drug, plus chemotherapy, shows a significant survival benefit.
Hospitals could receive $75 billion in funding to combat coronavirus.
Olumiant trial joins other RA drug trials, including hydroxychloroquine.
An NIH trial on the controversial anti-malaria medication is underway.
More COVID-19 patients receive anti-malaria drug despite controversy.
Agency issues Emergency Use Authorization for hydroxychloroquine sulfate, along with a novel COVID-19 test.
Clinical trial results were similar to those of the drug in adults.
First point-of-care test to detect coronavirus cleared.
The agency takes other steps to make COVID-19 tests more available.
New measures taken due to depression, suicidal thoughts, and other adverse events.
Discover the latest news on COVID-19 vaccine and drug development.
Companies cited over false coronavirus claims include The Jim Bakker Show.
Isatuximab-irfc (Sarclisa, Sanofi-Aventis) was approved in combination with pomalidomide and dexamethason to treat adult patients with multiple myeloma who have received at least two prior therapies.
Inhaler is the first generic approval of its kind.
Express Scripts’ annual Drug Trend Report highlights top contributors to prescription drug spending in 2019.
Treatment is first non-statin LDL-C lowering treatment approved in years.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
ALK Testing Strategies and Navigating First-Line Treatment Options in Advanced NSCLC
2
How PBMs are tackling behavioral health
3
ALK-Positive NSCLC: Epidemiology, Prognosis, and the Critical Role of Biomarker Testing
4
Most commercial plans cover SC and IV oncology therapies at parity
5